120,035 Shares in PetMed Express, Inc. $PETS Purchased by Truffle Hound Capital LLC

Truffle Hound Capital LLC acquired a new stake in shares of PetMed Express, Inc. (NASDAQ:PETS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 120,035 shares of the company’s stock, valued at approximately $399,000. Truffle Hound Capital LLC owned about 0.58% of PetMed Express as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PETS. R Squared Ltd purchased a new position in shares of PetMed Express in the 2nd quarter valued at approximately $34,000. Goldman Sachs Group Inc. lifted its holdings in shares of PetMed Express by 59.3% during the first quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock worth $139,000 after purchasing an additional 12,360 shares during the period. Caption Management LLC purchased a new position in PetMed Express in the 1st quarter valued at $242,000. American Century Companies Inc. grew its position in PetMed Express by 80.1% in the 1st quarter. American Century Companies Inc. now owns 60,629 shares of the company’s stock valued at $254,000 after buying an additional 26,967 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in PetMed Express in the 1st quarter valued at $295,000. 73.33% of the stock is owned by institutional investors and hedge funds.

PetMed Express Stock Down 2.0%

Shares of NASDAQ PETS opened at $1.96 on Tuesday. The stock has a market capitalization of $41.19 million, a price-to-earnings ratio of -6.53 and a beta of 0.73. PetMed Express, Inc. has a 52 week low of $1.93 and a 52 week high of $6.85. The firm has a 50-day moving average price of $2.59 and a 200 day moving average price of $3.13.

PetMed Express (NASDAQ:PETS) last issued its earnings results on Tuesday, October 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.60). PetMed Express had a negative net margin of 2.76% and a negative return on equity of 6.76%. The company had revenue of $46.47 million during the quarter. Equities research analysts expect that PetMed Express, Inc. will post 0.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PETS has been the subject of several recent analyst reports. Wall Street Zen cut shares of PetMed Express from a “hold” rating to a “sell” rating in a research note on Saturday, October 18th. Weiss Ratings reissued a “sell (d)” rating on shares of PetMed Express in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of PetMed Express from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. One investment analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Sell” and an average target price of $3.20.

PetMed Express Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.